ATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica.
Continue readingContact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
Industry News: How New Knowledge about Cancer Is Changing Clinical Trials
Over the last two decades, biomedical researchers have begun to unravel cancer’s immense complexity, drilling down to the molecular level to better understand the genetic and biological changes that drive how cancers develop, grow, and spread.
Continue readingInternational Thoracic Oncology Experts – ESMO Panel Discussion
ATOMIC Director Ross Camidge MD, PhD, draws out novel opinions across the field of thoracic oncology from a panel of international experts discussing their favorite ESMO abstracts from 2022.
Continue readingIndustry News: Mediterranean diet improves immunotherapy response rates and progression-free survival in advanced melanoma
Eating a Mediterranean diet, rich in fiber, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients.
Continue readingIndustry News: Brain MRI surveillance needed for TKl-treated ALK or ROS7-positive NSCLC
Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.
Continue readingIndustry News: Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer
Novel Oral Suspension Formulation of Abiraterone Acetate Designed to Address Needs of Metastatic Prostate Cancer Patients Who Have Difficulty Swallowing (Dysphagia), an Issue for 20 to 30 Percent of Prostate Cancer Patients
Continue readingIndustry News: Insightec receives FDA IDE approval for prostate cancer comparative study using high intensity focused ultrasound
Insightec announced that it has received FDA approval for an investigational device exemption (IDE) for a clinical comparative study of the Exablate Prostate system used to treat diseased prostate tissue. This study will evaluate the safety and efficacy of focal treatment using high intensity focused ultrasound when compared to active surveillance in men living with prostate cancer.
Continue readingIndustry News: Patients Took Drug Dostarlimab For Six Months, Results Showed Their Tumors Disappeared
Recently a small cancer study showed the unprecedented result of 100 percent of participants in remission. A study at Memorial Sloan Kettering Cancer Center in New York showed encouraging results using immunotherapy treatment with the drug Dostralimab.
Continue readingIndustry News: New Study Shows DCT Methods Helped Lung Cancer Trial Enrollment as COVID Surged
Remote and flexible trial approaches have been a hallmark of clinical trials during the pandemic and are widely believed to have been the primary factor in keeping trials open and operating. There is evidence showing that such measures as telehealth visits, off-site diagnostic/monitoring procedures and remote consenting were at least partially responsible for the ability of lung cancer trials to weather the storm.
Continue readingHelping People with Cancer Manage their Health: Home-based Clinical Trial
A collaborative virtual clinical trial will study the effectiveness of two digital therapeutics. Both digital therapeutics are anticipated to have an impact on mental and physical health when used adjunctively with multidisciplinary oncology care regimens.
Continue reading